Connect Biopharma has completed enrollment for its Phase 2 Seabreeze STAT Asthma study testing rademikibart, a new antibody treatment for acute asthma exacerbations. The study enrolled 160 participants globally and aims to evaluate safety and efficacy alongside standard care. Topline data is expected in early September 2026, with a similar COPD study enrollment finishing soon. The company plans to meet the FDA later this year to discuss Phase 3 trials, advancing rademikibart as a potential new biologic therapy for asthma and COPD patients.
SpaceX's 2026 IPO on Nasdaq under the ticker SPCX has established a public market benchmark for the space launch economy, prompting investors to seek other investable companies in the sector. Rocket Lab Corporation (Nasdaq: RKLB) stands out with reco...
The Lemon Reps, a national lemon law firm based in Beverly Hills, has recovered over $3.2 million and resolved more than 1,500 defective vehicle cases in the past year. They report an average settlement time of about 90 days, helping consumers effici...
On June 26, 2026, the Nasdaq Closing Cross recorded a historic trading volume of 4.59 billion shares worth $334 billion in just 1.63 seconds during the semi-annual Russell US Index reconstitution. This event reflects shifts in market capitalization a...
AI/R Compass UOL, a subsidiary of AI/R specializing in Agentic AI, won the 2026 AWS Partner Network Award as Consulting Partner of the Year for Brazil. This award highlights the company's leadership in data engineering and complex infrastructure usin...
Chainlink's price has recently fallen below its 200-day moving average but is showing signs of a bullish reversal as it holds above the critical $7.20 support level for the third time. Sellers appear to be losing momentum, with reduced volatility and...
